Fulgent's High-Stakes Pivot: Can New Drugs and AI Outrun Key Losses?

EL MONTE, CA – February 27, 2026 – Fulgent Genetics reported a year of robust top-line growth for 2025, yet its financial results reveal a company at a critical inflection point. While revenue climbed 14% to $322.7 million for the full year, the diagnostics and therapeutics firm posted a significant GAAP loss of $60.5 million. This mixed performance sets the stage for a challenging 2026, as the company braces for the departure of its largest customer while simultaneously executing an ambitious transformation strategy built on strategic acquisitions, artificial intelligence, and a burgeoning drug development pipeline.

A Tale of Two Financials: Growth vs. Profitability

Fulgent's 2025 financial report paints a complex picture that requires looking beyond the headline revenue figures. The fourth quarter saw revenues climb 9% year-over-year to $83.3 million, continuing a trend of steady growth in its laboratory services business. However, beneath this growth lies a stark contrast in profitability metrics. The company reported a GAAP loss of $23.4 million for the quarter and $60.5 million for the full year.

This is what some analysts call a "dual reality," where the company tells a different story using non-GAAP (Generally Accepted Accounting Principles) measures. On a non-GAAP basis, Fulgent was profitable, posting an income of $5.2 million in the fourth quarter and $13.2 million for the full year. The chasm between these two figures is explained by several significant non-cash and one-time expenses excluded from the non-GAAP calculation. These include $39.6 million in equity-based compensation, $8.0 million in amortization of intangible assets, a $9.9 million impairment loss on an investment, and nearly $2 million in acquisition-related costs for the year.

While these adjustments are common, the sheer scale of the difference highlights the costs associated with Fulgent's growth and strategic investments. Chief Financial Officer Paul Kim noted the progress made, stating, “In 2025, we demonstrated strong momentum as we delivered growth in our laboratory services business and drove margin improvements due to streamlined operations and enhanced efficiencies.” However, the outlook for 2026 suggests continued pressure, with a projected non-GAAP loss of approximately $1.45 per share, reflecting ongoing investments and the financial impact of its evolving business mix.

Bracing for Impact: The Customer Defection and Acquisition Lifeline

The most significant headwind facing Fulgent in 2026 is the planned departure of its single largest customer. In 2025, this one client accounted for a staggering $70.8 million in revenue, or 22% of the company's total. This customer's decision to move its testing volume in-house will create an estimated $59 million revenue gap, with the sharpest impact expected in the first half of the year.

In response, Fulgent has orchestrated a swift and decisive counter-maneuver through strategic acquisitions. The company announced its plan to acquire Bako Diagnostics and StrataDx for a combined price of approximately $55.5 million in cash. These deals, expected to close in March, are not merely a financial plug; they represent a strategic deepening of Fulgent's capabilities in anatomic pathology. Bako is a national provider of specialty lab services, including molecular genetics and peripheral neuropathy testing, while StrataDx specializes in dermatopathology.

The company anticipates these acquisitions will contribute between $50 million and $55 million in revenue in 2026, effectively offsetting most of the lost business. As CFO Paul Kim explained, "our revenue guidance reflects the impact of our largest customer moving a significant volume of its work in-house, but we believe the strategic initiatives we have made coupled with potential contribution from the acquisition of Bako and Strata Dx will help partially or fully offset this impact in the second half of the year."

Beyond the revenue replacement, the acquisitions are set to transform Fulgent's operational footprint. The addition of Bako's national sales force will nearly double the size of Fulgent's pathology sales team, significantly expanding its market reach. Crucially, this move will also de-risk the company's revenue base; post-acquisition, Fulgent projects that no single customer will account for more than 10% of its total revenue, a dramatic reduction from the 22% concentration seen in 2025.

The Long Game: Betting on AI and a Therapeutic Future

While acquisitions address the immediate revenue challenge, Fulgent's long-term vision is anchored in technology and therapeutic innovation. The company is making substantial investments to transform from a diagnostics provider into a fully integrated precision medicine company.

A key pillar of this strategy is the integration of artificial intelligence and digital pathology into its lab services. The company has already achieved 100% digital pathology adoption across its cases, powered by its proprietary imaging management system, "Ezeopath." This platform is being enhanced with internal and third-party AI modules designed to improve diagnostic efficiency and quality—enhancements Fulgent plans to roll out across the newly acquired Bako and StrataDx operations. Ming Hsieh, Chairman and CEO, stated, “The laboratory services business sustained momentum, and the business is benefiting from the investments we made in AI and digital pathology solutions.”

The other half of Fulgent's ambitious future lies in its therapeutic development business. The company is advancing a pipeline of novel cancer drug candidates and plans to spend approximately $26 million on this effort in 2026. The lead candidate, FID-007, is a nano-encapsulated form of the chemotherapy drug paclitaxel designed to target tumors more effectively while minimizing side effects. Having recently completed enrollment for its Phase 2 trial in Head and Neck Squamous Cell Carcinoma, Fulgent is preparing for a potential Phase 3 trial as early as 2027. Interim data is highly anticipated at the American Society of Clinical Oncology (ASCO) meeting in June 2026. A second candidate, FID-022, is progressing through Phase 1 trials for various solid tumors.

A Fortress Balance Sheet for a Transitional Year

Underpinning this complex strategy of acquisitions, technological investment, and drug development is a remarkably strong balance sheet. Fulgent ended 2025 with approximately $705.5 million in cash, cash equivalents, and marketable securities, providing a substantial cushion to navigate its transitional year.

This financial fortress gives the company the flexibility to absorb near-term losses while funding its long-term bets. The projected 2026 year-end cash balance of approximately $685 million accounts for the ~$56 million spent on acquisitions, ~$26 million on therapeutic development, and ~$12 million in other capital purchases. However, this forecast hinges on one critical variable: the receipt of a delayed $106 million federal tax refund, which was held up by a government shutdown in late 2025. Assuming this cash arrives as expected, Fulgent is well-capitalized to weather the storm of its customer loss and continue funding the strategic pivot it believes will secure its future as a leader in precision medicine.